Destiny Pharma's nasal spray project already delivering "more than hoped for" | News Direct

Destiny Pharma's nasal spray project already delivering "more than hoped for"

Destiny Pharma PLC
News release by Destiny Pharma PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | May 02, 2023 07:30 AM Eastern Daylight Time

 

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than hoped for" and that it will be "really interesting to see where [it] goes next."

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

HealthBiotechPharmaInfluenzaCOVIDNasal SprayVaccination